Viz.ai and Cortechs.ai Forge AI Alliance for Neurodegenerative Disease

SAN FRANCISCO, CA – July 09, 2026 – Viz.ai, a dominant force in AI-powered care coordination, is making a significant strategic move into the complex world of neurodegenerative disease. The company announced a collaboration with Cortechs.ai, a leader in quantitative neuroimaging, to integrate advanced brain analysis tools directly into its widely used platform. This partnership, beginning with a focus on Multiple Sclerosis (MS), signals a new chapter for the AI innovator and could reshape how chronic neurological conditions are diagnosed and managed across the United States.

The deal brings together two industry powerhouses: Viz.ai, whose care coordination platform is deployed in nearly 2,000 U.S. hospitals, and Cortechs.ai, whose NeuroQuant software provides FDA-cleared quantitative analysis of MRI scans. By embedding these precise analytics into a platform known for accelerating clinical action, the collaboration aims to solve a critical challenge in neurology: the early and objective tracking of devastating diseases.

A New Frontier in Precision Neurology

For decades, managing neurodegenerative diseases like MS has been a difficult balance of clinical observation and subjective interpretation of medical images. Neurologists and radiologists visually inspect MRI scans for changes in brain lesions or atrophy—subtle shifts that signal disease progression. This process can be time-consuming and variable, depending on the clinician's expertise. The collaboration between Viz.ai and Cortechs.ai aims to replace this subjectivity with data-driven precision.

Cortechs.ai's NeuroQuant MS software automates the analysis of MRI scans, delivering objective, reproducible measurements of lesion volume, count, and changes over time. It can identify new, enlarging, or shrinking lesions with a level of accuracy that is difficult to achieve by eye alone. This moves the clinical question from a subjective "Does it look worse?" to a quantitative "By how much has it changed?" This level of detail is crucial for MS, a condition where numerous disease-modifying therapies are available, and timely treatment adjustments can significantly impact a patient's long-term quality of life.

By integrating these quantitative reports directly into the Viz.ai platform, the entire care team—from the radiologist interpreting the scan to the neurologist managing the patient—receives this critical information simultaneously and in real-time. This unified workflow promises to accelerate clinical decision-making, ensuring that subtle signs of disease progression are not missed and that patients are put on the optimal treatment path faster.

“Viz.ai's core mission has always been to increase access to life-saving treatments,” said Dr. Tim Showalter, Chief Medical Officer at Viz.ai. “This collaboration with Cortechs.ai extends that commitment into neurodegenerative disease, an area with profound unmet need and enormous potential—particularly where earlier patient identification and disease characterization can meaningfully change the treatment trajectory.”

The Strategic Playbook: From Stroke to Chronic Illness

This expansion into neurodegenerative disease is a classic move from the Viz.ai playbook. The company first rose to prominence by transforming acute stroke care with its Viz LVO software, which uses AI to detect large vessel occlusions and automatically alert stroke specialists. The platform dramatically reduced treatment times and, in a landmark move, became the first AI software to receive a New Technology Add-on Payment (NTAP) from the Centers for Medicare & Medicaid Services (CMS), validating its clinical and economic value.

Now, Viz.ai is applying that same model to the vast and growing market of chronic disease. The strategy is clear: identify a complex condition with a clear unmet need, partner with a best-in-class technology provider, and leverage its massive hospital network for immediate, at-scale deployment. With a presence in nearly 2,000 hospitals, Viz.ai offers Cortechs.ai an unparalleled distribution channel, effectively turning a specialized diagnostic tool into a network-wide capability overnight.

This shift from acute interventions to long-term disease management marks a significant evolution for the company. While stroke care involves a single, critical event, managing MS requires continuous monitoring over years or decades. By embedding quantitative tracking into its coordination platform, Viz.ai is positioning itself as an essential infrastructure provider for the future of chronic care management.

Building an Integrated AI Ecosystem

This partnership also reflects a broader industry trend away from isolated, single-purpose AI tools and toward integrated, enterprise-wide platforms. Hospital systems are increasingly wary of adopting "point solutions" that exist in a silo and require clinicians to juggle multiple, disconnected applications. Viz.ai's success has been built on its ability to weave AI-driven insights directly into the existing clinical workflow.

“We believe the future of healthcare AI will be built on connected platforms, not isolated point solutions,” said Kyle Frye, CEO at Cortechs.ai. “Our partnership with Viz.ai is a powerful example of that vision, combining Viz.ai’s care coordination platform with the trusted quantitative insights of NeuroQuant and NeuroQuant MS platforms to accelerate innovation.”

This ecosystem approach is central to Viz.ai's concept of "agentic AI"—intelligent systems that don't just detect a problem but also orchestrate the necessary human response. The company’s recent ISO/IEC 42001 certification, an international standard for AI management systems, underscores its commitment to deploying this powerful technology responsibly and effectively. By acting as an integration hub, the platform makes it easier for hospitals to adopt best-in-class AI from partners like Cortechs.ai without adding workflow friction, a major barrier to technological adoption in healthcare.

Charting the Course for Market Adoption

With the technology and strategy in place, the final hurdles are regulatory and financial. Here, too, the collaboration is on solid ground. Cortechs.ai’s NeuroQuant suite is already FDA-cleared, removing a significant regulatory obstacle. Furthermore, Viz.ai has a proven track record of navigating the complex U.S. reimbursement landscape.

Following its groundbreaking NTAP for stroke AI, the company has successfully worked to establish CPT codes for AI-powered analysis in cardiology. This experience provides a clear roadmap for establishing the economic case for its new neurodegenerative offering. Demonstrating that quantitative analysis leads to better treatment decisions and improved patient outcomes will be key to securing reimbursement, which in turn drives widespread adoption.

Both companies have indicated that the initial focus on MS is just the beginning. The NeuroQuant technology has capabilities for assessing other conditions like Alzheimer's, epilepsy, and traumatic brain injury. This partnership therefore lays the foundation for a comprehensive neurodegenerative disease suite on the Viz.ai platform, opening up vast future markets as new therapies for these challenging conditions continue to emerge.